Neil Flanzraich

Mr. Flanzraich brings to Alzheon more than 30 years of executive leadership, operations, and legal experience with pharmaceutical and life sciences companies. Mr. Flanzraich was an early investor in Alzheon and served in the role of Chief Business Officer of Alzheon as a consultant to the company from February to May 2018.

Mr. Flanzraich is the Executive Chairman of Cantex Pharmaceuticals, Inc., a privately-owned biotech company, which is developing drugs for cancer. Previously, he was Cantex’s, Chief Executive Officer. Mr. Flanzraich served as Vice Chairman and President of IVAX Corporation, an international pharmaceutical company, for over seven years, prior to its sale in 2006 to TEVA Pharmaceutical Industries, Ltd. for an enterprise value of $10 billion. Prior to his tenure at IVAX, Mr. Flanzraich served as Chairman of the Life Sciences Legal Practice Group of Heller Ehrman LLP, a law firm. Previously Mr. Flanzraich worked at Syntex Corporation, an international pharmaceutical company, where, as the Senior Vice President, and a member of both the Corporate Operating and Corporate Executive Committees, he made major contributions to the value of the company, which was acquired by Roche in 1994 for $5.3 billion.

Mr. Flanzraich was an early investor and member of the board of directors of Chipotle Mexican Grill, Inc. (NYSE: CMG), and is currently its lead independent director. Mr. Flanzraich was the lead independent director of Equity One, Inc. (NYSE: EQY), prior to its acquisition by Regency Centers Corporation in 2017. He was an independent director of Continucare Corporation (NYSE: CNU), a company with primary care centers, from 2002 to its sale in 2011. Mr. Flanzraich received an AB from Harvard College and a JD from Harvard Law School.

Mr. Flanzraich is qualified to serve on the board of directors because of his business expertise and extensive experience in the pharmaceutical and biotechnology industries.